IQVIA (NYSE:IQV) Hits New 12-Month Low – Time to Sell?

IQVIA Holdings Inc. (NYSE:IQV) hit a new 52-week low on Monday . The stock traded as low as $146.06 and last traded at $147.20, with a volume of 197303 shares changing hands. The stock had previously closed at $154.73.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the company. William Blair restated an “outperform” rating on shares of IQVIA in a research note on Wednesday, December 11th. Mizuho reduced their price target on IQVIA from $242.00 to $210.00 and set an “outperform” rating for the company in a report on Wednesday. Robert W. Baird cut their price target on IQVIA from $212.00 to $210.00 and set a “neutral” rating for the company in a report on Tuesday, January 21st. UBS Group decreased their price objective on shares of IQVIA from $260.00 to $255.00 and set a “buy” rating on the stock in a report on Friday, February 7th. Finally, Bank of America lowered their price target on shares of IQVIA from $255.00 to $235.00 and set a “buy” rating on the stock in a report on Friday, December 13th. Five equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, IQVIA presently has a consensus rating of “Moderate Buy” and an average target price of $247.10.

IQVIA Stock Down 3.5 %

The firm has a market cap of $24.58 billion, a price-to-earnings ratio of 18.70, a PEG ratio of 1.99 and a beta of 1.46. The firm has a 50 day moving average of $186.31 and a 200 day moving average of $201.80. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing analysts’ consensus estimates of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. As a group, sell-side analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Institutional Trading of IQVIA

Several hedge funds have recently bought and sold shares of IQV. Synergy Asset Management LLC acquired a new stake in shares of IQVIA in the 4th quarter worth about $33,000. GKV Capital Management Co. Inc. acquired a new position in IQVIA during the 4th quarter valued at about $39,000. Lee Danner & Bass Inc. bought a new position in shares of IQVIA in the fourth quarter valued at approximately $44,000. Zions Bancorporation N.A. raised its position in IQVIA by 55.2% in the 4th quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company’s stock valued at $47,000 after buying an additional 85 shares during the last quarter. Finally, Versant Capital Management Inc grew its stake in shares of IQVIA by 46.0% in the 4th quarter. Versant Capital Management Inc now owns 295 shares of the medical research company’s stock worth $58,000 after acquiring an additional 93 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.